Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells
Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …